Hyderabad, India, 17 February 2026: Rx Propellant, India’s leading science and R&D infrastructure platform established by Actis, a leading growth market investor in sustainable infrastructure, and part of General Atlantic, a global investment leader, today announced an investment of USD 100 Mn to develop a new, large-format life sciences campus in Genome Valley, Hyderabad as part of its long-term commitment to strengthening India’s life sciences ecosystem. The project will comprise development of more than 1 million square feet of advanced laboratory infrastructure to be delivered in phases over the next six years.
Planned as a single, integrated campus with multiple blocks, the project will be the largest life sciences campus in Genome Valley designed for corporations looking to lease buildings with well-managed resilient support infrastructure. The campus will cater to Indian and global life sciences companies seeking scalable and quality infrastructure for R&D and allied operations, delivering institutional-grade laboratory spaces, bringing together fully compliant buildings and high-performance electromechanical services in a robust design.
Ashish Singh, CEO and Managing Director, Rx Propellant, said: “India’s life sciences sector is entering a phase of decisive scale-up, and buildings and infrastructure solutions must evolve in parallel to support this growth. This investment reflects our conviction in Genome Valley, Hyderabad as a long-term anchor for global and domestic R&D. Rx Propellant already has an established track record in Genome Valley, with its 1GV and 3GV campuses already 100% leased, hosting a mix of marquee global and Indian life sciences companies. Sustained demand for high quality buildings in Genome Valley provides a strong foundation for our next phase of growth as we continue delivering high-quality infrastructure at scale, helping our customers expand with confidence and continuity.”
Beyond Hyderabad, Rx Propellant is also developing Navi Mumbai Research District (NMRD) spread over a site of 16 acres, planned as Mumbai’s largest cohesive ecosystem for science and research. Together, these investments reflect the Rx Propellant’s strategy of creating long-term, institutional-quality science and R&D infrastructure across India’s most important innovation clusters.
Sustainability remains a core pillar of Rx Propellant’s development philosophy. All existing campuses in its portfolio are planned in line with globally recognised green building standards, with LEED and IFC EDGE certifications embedded in design and operations. This approach ensures long-term resource efficiency and reduces environmental impact across the asset lifecycle.
Brian Chinappi, Managing Director and Global Head of Real Estate & Data Centers at Actis, said: “High-quality physical infrastructure is foundational to building globally competitive life sciences ecosystems. With increasing global interest in research, development and manufacturing partnerships within India, this investment underscores our conviction in India and in Hyderabad’s role as a leading R&D hub. Expanding Rx Propellant’s footprint in Genome Valley is a strategic step toward building a network of world-class life sciences campuses in India that can support companies at every stage of their growth journey from R&D to manufacturing.”
Genome Valley has evolved over the past two decades into India’s most established life sciences cluster, anchored by a dense concentration of pharmaceutical and biotechnology companies, research institutions and specialised infrastructure. The region is supported by a deep and experienced talent pool, reflecting Hyderabad’s long-standing strengths in pharmaceuticals, contract services and vaccines. Sustained public and private investment has enabled Genome Valley’s transition into a fully integrated R&D and innovation ecosystem, attracting leading global and Indian life sciences enterprises. Rx Propellant’s upcoming campus is expected to further promote the region’s position as a preferred destination for innovation-driven companies seeking strategic, scalable and globally benchmarked infrastructure solutions.
About Rx Propellant
Rx Propellant is India’s leading science & R&D infrastructure platform, focused on shaping the next generation of research and manufacturing environments tailored to the needs of high-growth science companies. Backed by Actis (a General Atlantic company), Rx Propellant is building world-class science-led clusters across Hyderabad and Navi Mumbai with a development pipeline of around 4 million square feet. All projects are designed with best-in-class specifications and sustainability standards to support operations from concept to commercialisation.
About Actis
Actis is a leading growth market investor in sustainable infrastructure. Actis invests in structural themes that aim to support long-term, equitable growth in defensive, critical infrastructure across energy transition, digitalisation transition, and supply chain transformation.
Actis believes that the firm’s decades of global experience, operational know-how and strong culture allow it to create global sustainability leaders at scale. Actis is a signatory to the Principles for Responsible Investment (PRI), an investor initiative supported by the United Nations.
In October 2024, Actis joined forces with General Atlantic, a leading global growth investor, creating a diversified, global investment platform, together we have approximately $123 billion in combined assets under management. Actis operates as General Atlantic’s sustainable infrastructure business. This strategic combination further enhances Actis’ focus as a leader in global sustainable infrastructure.
You can learn more about Actis at www.act.is
For more information, visit: www.rxpropellant.com
